Communiqués de presse
Archives
Cellectis and VitamFero signed an agreement
2011/06/06
Cellectis and VitamFero Collaborate to Develop Vaccines against Parasitic Infection
Cellectis (Alternext: ALCLS), the genome engineering specialist, and VitamFero, a biotech company of the Genopole® portfolio developing new vaccines against parasite infections, announced the signing of a research, development and licensing partnership agreement.
This agreement will grant VitamFero access to Cellectis’ proprietary meganuclease technology for the design and development of a new generation of living attenuated vaccines.
In order to receive
Genopole® press releases®,
please provide your coordinates
to Press Service
